ENTRY       D05031                      Drug
NAME        Migalastat hydrochloride (JAN/USAN);
            Galafold (TN)
PRODUCT     GALAFOLD (Amicus Therapeutics US)
FORMULA     C6H13NO4. HCl
EXACT_MASS  199.0611
MOL_WEIGHT  199.6327
REMARK      Therapeutic category: 3999
            ATC code: A16AX14
            Chemical structure group: DG02691
            Product (DG02691): D05031<JP/US>
EFFICACY    Lysosomal storage disease treatment, Pharmacological chaperone
  DISEASE   Fabry disease (GLA variant) [DS:H00125]
COMMENT     Pharmacological chaperone
TARGET      GLA* [HSA_VAR:2717v2] [HSA:2717] [KO:K01189]
  PATHWAY   hsa00600(2717)  Sphingolipid metabolism
            hsa04142(2717)  Lysosome
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
               A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
                A16AX Various alimentary tract and metabolism products
                 A16AX14 Migalastat
                  D05031  Migalastat hydrochloride (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Migalastat
               D05031  Migalastat hydrochloride (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D05031  Migalastat hydrochloride (JAN/USAN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Glycosidases
                GLA* [HSA_VAR:2717v2]
                 D05031  Migalastat hydrochloride (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D05031
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05031
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D05031
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D05031
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D05031
DBLINKS     CAS: 75172-81-5
            PubChem: 47206758
            LigandBox: D05031
ATOM        12
            1   C1y C    10.9200  -14.9800
            2   C1y C    10.9200  -16.3800
            3   C1y C    12.1324  -17.0800
            4   C1y C    13.3449  -16.3800
            5   C1x C    13.3449  -14.9800
            6   N1x N    12.1324  -14.2800
            7   C1b C     9.7076  -14.2800
            8   O1a O     9.7076  -17.0800
            9   O1a O    12.1324  -18.4798
            10  O1a O    14.5760  -17.0910
            11  O1a O     8.5121  -14.9704
            12  X   Cl   17.3600  -15.1900
BOND        11
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 1
            7     1   7 1 #Up
            8     2   8 1 #Up
            9     3   9 1 #Up
            10    4  10 1 #Down
            11    7  11 1
///
